Companies › Tenaya Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TN-201 Recombinant AAV9 delivering MYBPC3 transgene | MYBPC3 | Phase 1 | Hypertrophic Cardiomyopathy | Aug 2027 |
| TN-401 AAV9 gene therapy delivering PKP2 transgene | PKP2 | Phase 1 | Arrhythmogenic Right Ventricular Cardiomyopathy | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05836259 | TN-201 | Phase 1 | Hypertrophic Cardiomyopathy | Cardiovascular | Aug 2027 |
| NCT06228924 | TN-401 | Phase 1 | Arrhythmogenic Right Ventricular Cardiomyopathy | Cardiovascular | Oct 2029 |
Cash and short-term investments of $67m on 2026-09-30; operating cash outflow about $54m a year; runway about 15 months at that burn, to Dec 2027
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Rocket Pharmaceuticals Lexeo Therapeutics Edgewise Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.